Physician profile
Michael D Calabrese
NPI 1992782601
$1,761.13
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $460 · 2021: $763 · 2022: $286.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $240.77 | 2019-2021 | |
| Abbvie INC. | $207.71 | 2020-2022 | |
| Lilly USA, LLC | $193.32 | 2019-2021 | |
| Pfizer INC. | $146.44 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $137.71 | 2020-2022 | |
| Boston Scientific Corporation | $135.22 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $93.31 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.06 | 2019-2020 | |
| Glaxosmithkline, LLC. | $49.20 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.28 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $43.01 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $38.50 | 2020 | |
| Amgen INC. | $37.07 | 2019-2020 | |
| Mannkind Corporation | $34.48 | 2019-2020 | |
| Eisai INC. | $32.45 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30.82 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $23.08 | 2021 | |
| Amneal Pharmaceuticals LLC | $22.08 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.44 | 2020 | |
| Abbott Laboratories | $21.19 | 2020 | |
| Uswm, LLC | $19.44 | 2021 | |
| Amarin Pharma, INC. | $18.66 | 2020 | |
| Scilex Pharmaceuticals INC. | $17.04 | 2021 | |
| Genentech USA, INC. | $16.09 | 2021 | |
| Allergan, INC. | $15.11 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Calabrese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.